In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

French National Inst. Health & Med. Res. (INSERM)

www.inserm.fr

Latest From French National Inst. Health & Med. Res. (INSERM)

Venture Funding Deals, January 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced November through December 2015.

BioPharmaceutical Medical Device

Versant Launches Inception IBD, A New Company With Old Roots

Versant and Celgene have partnered again to launch a build-to-buy biotech, this time focusing on inflammatory bowel disease.

BioPharmaceutical Strategy

Venture Funding Deals, November 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced September through October 2015.

BioPharmaceutical Medical Device

Device/Diagnostics Quarterly Deal Statistics, Q1 2015

Device financing rose slightly to $934 million in Q1, while acquisition value was down to just over $4 billion. Diagnostics fundraising dropped significantly to $597 million; M&A activity was dominated by NGS and Roche's transaction with Foundation Medicine.

Medical Device Deals
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register